Sienna and Minomic Enter Collaboration Agreement to Develop Pancreatic Cancer Test
-
Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10%.
-
There are no liquid biopsy assays for the early detection of pancreatic cancer.
-
There is independent evidence that the protein GPC-1 on exosomes is strongly elevated in the blood from pancreatic cancer patients.
-
Sienna will utilise its proprietary EXO-NETTM exosome capture technology to isolate exosomes, and Minomic will use its proprietary anti-GPC-1 antibody in a pilot study to test the feasibility of developing a proprietary pancreatic cancer assay.
Melbourne, Australia, 30 October 2019: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer- related tests, has entered into a research collaboration agreement with Sydney-based Minomic International Ltd, to develop a proprietary test for the early detection of pancreatic cancer.
For further information please download the attached PDF:
Download this document
